Literature DB >> 23650174

Relationship of in vitro synergy and treatment outcome with daptomycin plus rifampin in patients with invasive methicillin-resistant Staphylococcus aureus infections.

Warren E Rose1, Andrew D Berti, Jacob B Hatch, Dennis G Maki.   

Abstract

We report the findings of a study examining the relationship between in vitro daptomycin-rifampin synergy and the therapeutic outcome of 12 patients with complex deep methicillin-resistant Staphylococcus aureus (MRSA) infections treated for prolonged periods with this combination. Checkerboard synergy was found in nine cases and was 100% predictive of therapeutic success; absence of synergy was found in three cases, two of which were therapeutic failures (P = 0.045). No relationship was observed between synergy and outcome by time-kill assessment. Checkerboard synergy may predict clinical response to daptomycin plus rifampin for complex invasive MRSA infections requiring prolonged treatment.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23650174      PMCID： PMC3697323          DOI： 10.1128/AAC.00325-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms.

Authors:  H Ceri; M E Olson; C Stremick; R R Read; D Morck; A Buret
Journal:  J Clin Microbiol       Date:  1999-06       Impact factor: 5.948

2.  Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations.

Authors:  Molly E Steed; Celine Vidaillac; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

3.  Synergy, antagonism, and what the chequerboard puts between them.

Authors:  F C Odds
Journal:  J Antimicrob Chemother       Date:  2003-06-12       Impact factor: 5.790

4.  Activity of daptomycin alone and in combination with rifampin and gentamicin against Staphylococcus aureus assessed by time-kill methodology.

Authors:  Kim Credito; Gengrong Lin; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

5.  Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America.

Authors:  Douglas R Osmon; Elie F Berbari; Anthony R Berendt; Daniel Lew; Werner Zimmerli; James M Steckelberg; Nalini Rao; Arlen Hanssen; Walter R Wilson
Journal:  Clin Infect Dis       Date:  2012-12-06       Impact factor: 9.079

6.  Antimicrobial activities of ceragenins against clinical isolates of resistant Staphylococcus aureus.

Authors:  Judy N Chin; Michael J Rybak; Chrissy M Cheung; Paul B Savage
Journal:  Antimicrob Agents Chemother       Date:  2007-01-08       Impact factor: 5.191

7.  Clinical experience with daptomycin for the treatment of patients with documented gram-positive septic arthritis.

Authors:  Graeme N Forrest; Brian J Donovan; Kenneth C Lamp; Lawrence V Friedrich
Journal:  Ann Pharmacother       Date:  2008-01-22       Impact factor: 3.154

8.  Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.

Authors:  O Murillo; C Garrigós; M E Pachón; G Euba; R Verdaguer; C Cabellos; J Cabo; F Gudiol; J Ariza
Journal:  Antimicrob Agents Chemother       Date:  2009-07-27       Impact factor: 5.191

9.  Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE).

Authors:  John F Mohr; Lawrence V Friedrich; Sara Yankelev; Kenneth C Lamp
Journal:  Int J Antimicrob Agents       Date:  2009-02-06       Impact factor: 5.283

10.  Clinical experience with daptomycin for the treatment of patients with osteomyelitis.

Authors:  Kenneth C Lamp; Lawrence V Friedrich; Luke Mendez-Vigo; Rene Russo
Journal:  Am J Med       Date:  2007-10       Impact factor: 4.965
View more
  6 in total

1.  Should daptomycin-rifampin combinations for MSSA/MRSA isolates be avoided because of antagonism?

Authors:  C Stein; O Makarewicz; C Forstner; S Weis; S Hagel; B Löffler; M W Pletz
Journal:  Infection       Date:  2016-01-21       Impact factor: 3.553

Review 2.  Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.

Authors:  Steven Y C Tong; Joshua S Davis; Emily Eichenberger; Thomas L Holland; Vance G Fowler
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

3.  A study on combination of daptomycin with selected antimicrobial agents: in vitro synergistic effect of MIC value of 1 mg/L against MRSA strains.

Authors:  Yi-Chien Lee; Pao-Yu Chen; Jann-Tay Wang; Shan-Chwen Chang
Journal:  BMC Pharmacol Toxicol       Date:  2019-05-06       Impact factor: 2.483

4.  Interaction Tolerance Detection Test for Understanding the Killing Efficacy of Directional Antibiotic Combinations.

Authors:  Jia-Feng Liu; Orit Gefen; Zi-Yin Zhang; Min-Min Liu; Maskit Bar-Meir; Nathalie Q Balaban
Journal:  mBio       Date:  2022-02-15       Impact factor: 7.786

Review 5.  Silver Nanoparticles and Its Mechanistic Insight for Chronic Wound Healing: Review on Recent Progress.

Authors:  Manoj Singh; Vanita Thakur; Vikas Kumar; Mayank Raj; Shivani Gupta; Nisha Devi; Sushil Kumar Upadhyay; Markéta Macho; Avik Banerjee; Daniela Ewe; Kumar Saurav
Journal:  Molecules       Date:  2022-08-30       Impact factor: 4.927

6.  Florfenicol As a Modulator Enhancing Antimicrobial Activity: Example Using Combination with Thiamphenicol against Pasteurella multocida.

Authors:  Chia-Fong Wei; Jui-Hung Shien; Shao-Kuang Chang; Chi-Chung Chou
Journal:  Front Microbiol       Date:  2016-03-30       Impact factor: 5.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.